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Abstract
Background:Axillary lymph node involvement in primary breast cancer is one of its most
important prognostic features. Thus any factors that may predict axillary lymph node
involvement in this setting could be potentially helpful in treatment planning and other
interventions.
Objective:The objective of this study was to evaluate clinical, pathological and immunohistochemical markers in univariate and multivariate analysis, which may be helpful predictors
of axillary lymph node involvement in breast cancer.
Method:A retrospective analysis of 555 cases. Of these 58% had axillary nodal positivity and
42% were negative.
Conclusion:Factors of no significance included patient’s age, height, weight, age of first
pregnancy, parity, marital status, menopausal status, family history of breast cancer, side of
tumor. In univariate analysis the age of menarche, duration of symptoms, tumor size, site in outer
quadrant, S phase and skin and nipple involvement all predicted axillary nodal involvement. The
length of breast-feeding, increased intraductal component and increased PCNA were inversely
proportional to nodal involvement. In multiple regression analysis however only size of the
tumor, involvement of the skin and nipple and disease in the outer quadrant of breast were the
factors, which assumed significance (JPMA 52:1 92;2002).
Introduction
Axillary node involvement is one of the most important prognostic factors for clinical outcome
in breast cancer1,2. In addition the presence or absence of axillary lymph node involvement by
tumor often dictates whether or not a patient will require adjunctive chemotherapy and/or
radiotherapy. Furthermore, the number of axillary lymph nodes involved may help to choose the
type and intensity of chemotherapy used3. It is therefore important to study the clinical,
histopathological and molecular factors, which may predict axillary lymph node involvement in
primary breast cancer. The potential impact of these factors assumes greater significance in those
instances when axillary dissection is not carried out. These factors may also help in
understanding the biological behavior of breast cancer.
It is increasingly appreciated that ethnic differences may result in a different biological behavior
of the same disease in patient populations4. There is much data on the behavior of breast cancer
in different ethnic groups from a country such as the United States. These ethnic groups include
the black, hispanic, white and other population groups5. Studies have indicated for example that
breast cancers may have a different outcome in these groups when they are compared to each

other. Data of such a nature from our part of the world are sparse. We therefore, analyzed the
breast cancer database at the Aga Khan University Hospital
(AKUH) to identify factors that may have a role in predicting axillary lymph node involvement
in the Pakistani female breast cancer patient population.
Patients and Methods
This was a retrospective analysis based on our breast cancer database. The breast cancer database
includes patients seen at the AKUH and all the referred cases from elsewhere between the years
1990 to 1998. A format has been designed to capture relevant clinicopathological information.
Cases that had been diagnosed at other hospitals however had as expected a variable format for
histological reporting. All immunohistochemical and prognostic marker studies were performed
in the pathology department of the AKUH.
Histological and Immuno Histochemical Methods
Breast specimens including modified radical mastectomies, simple mastectomies, wide local
excision and lumpectomies with axillary content and axillary node dissection were received from
all over the city and country through the main laboratory and 26 collection points. Specimens
were fixed in 10% buffered formalin solution. The specimens were grossed as per standard
protocol, which always included the measurement of tumor size and positivity of the excision
and posterior margins in the surgical specimens and retrieval of axillary nodes.
A minimum of 2 or 3 sections were submitted from the tumor mass. Immunohistochemical
studies were performed on formalin fixed, paraffin embedded tissue using the peroxide anti
peroxide method (PAP). Microwave oven pretreatment was performed for p53, erb2 (Her-2/
neu), proliferating nuclear cell antigen (PCNA), epidermal growth factor receptor (EGFR),
estrogen receptor (ER) and progesterone receptor (PR). Anti-human p53 protein, monoclonal
mouse antibody clone Do-7 (DAKO, Denmark), rabbit anti human - Her-2/neu oncoprotein
(DAKO, Denmark), monoclonal mouse anti-human EGFR, clone EGFR 1 (DAKO, Denmark),
polyclonal rabbit anticathepsin-D (California, USA) and monoclonal mouse anti PCNA clone PC
10 (DAKO, Denmark) were used. To study estrogen and progesterone receptor status
monoclonal mouse anti-human ER clone 1D5 (DAKO, Denmark) and rabbit anti-human
progesterone receptor (DAKO, Denmark) were employed. Paraffin sections were cut from tissue
block then incubated at room temperature (22-25o C) for 90 minutes with primary antibodies at
1:20 ul for ER and PR each, 1:10 ul for EGFR, 1:25 ul for p53, HERIneu and Cathepsin D each
and 1:100 ul for PCNA. After extensive washing, slides were incubated for 45 minutes with
secondary antibody. After a second washing step the slides were incubated for 45 minutes with
PAP complex. 3,3 diaminobenzidine tetrachloride was used as the final chromogen. Nuclei were
stained with hematoxylin.
The tumor cells were assessed semi-quantitatively for estrogen and progesterone receptors taking
both the intensity and distribution of specific staining. Percentage of positively stained tumor
cells were grouped into five categories - zero (no staining), 1 + (weak but detectable), 2 +
(mildly distinct), 3 + (moderately distinct) and 4 + (strong). For each specimen the score was
obtained by summing the percentage of cells staining at each intensity multiplied by the
weighted intensity of staining. A score of’ less than 74 was taken as negative, 75 - 99 as weak
positive, 100 - 119 as intermediate positive and greater than 120 as strongly positive.
For PCNA a tumor cell was designated as positive when there was any discernable nuclear
staining. The percentage of positive cells was determined in most immunoreactive areas.

Immunohistochemical stains for Her-2/neu and EGFR were interpreted as positive if membrane
staining was seen and this was graded semi-quantitatively on the intensity of staining and
number of cells stained and the absence of staining was considered negative, 10% staining as +,
25% as ++, 50% as +++ and greater than 50% as ++++. Cathepsin D staining exhibited as
nuclear and cytoplasm staining respectively and was graded for positivity semi quantitatively on
a scale of ++ to ++++ using similar criteria as above.
Statistical Methods
Data was summarized as the means with standard deviations for continuous variables and as
frequency and percents, odds ratio and 95% confidence intervals (CI) for categorical variables.
Chi square tests examining the association (lymph nodes involved versus not involved) and
breast cancer related factors were performed. Differences in means were evaluated by the
students t- test. A p-value of <0.05 was considered statistically significant.
Independent Predictors of Lymph nodes involvement among the breast cancer cases were
evaluated by multiple regression analysis. In the logistic regression model lymph node
involvement was the outcome variable. The analysis was carried out using the statistical software
SPSS version 8.0 by a qualified statistician (AS).
Results
There were a total of 555 cases of breast cancer in the database that were analyzed. Axillary
lymph nodes were involved in 323 (58%) of the cases. The mean number of lymph nodes
removed in each group was 14. A number of clinical, pathological and molecular factors were
analyzed for significance as predictive factors for axillary lymph node involvement in these
cases.
Continuous variables of no significance were the age, height, weight, age at first pregnancy and
the parity of the patient. Categorical variables of no significance included the marital status,
menopausal status, family history of breast cancer in first and second-degree relatives and the
side of the primary disease. Pathological categorical variables of no significance included the
tumor grade and the estrogen and progesterone receptor status. Molecular markers of no
significance included the P53 gene product; EGFR, PCNA, ploidy, c-erbB2 (Her-2/neu) and
cathepsin D. Factors which tested for significance in univariate analysis are shown in Table 1.

These factors included the age of menarche, length of breast-feeding in months, the duration of
symptoms before presentation to the clinic, disease in the outer quadrant of the breast, skin and
nipple involvement and tumors greater than 2 cms in size and the intraductal component.
Molecular features of significance included the PCNA value in percentage and the S phase
percentage. Thus when these characteristics were present the tumor had a greater propensity to
involve the axillary nodes except inversely for the intraductal component and the PCNA. In
multivariate analysis however only the tumor size, skin and nipple involvement and disease in

the outer quadrants of the breast were predictive for axillary node involvement (Table 2).

Discussion
There are several factors, which are increasingly recognized as having an effect on the biological
behavior of breast cancer. These include the clinical and demographic features, pathological
characteristics and the molecular factors within the breast tumor itself6. The exact role that each
of these may have on the biological behavior of breast cancer is an area of increasing interest,
including their role in the regional spread of the disease. However their impact on treatment until
now continued to be an area of research interest only6,7. Recently for example, the monoclonal
antibody Herceptin has been developed which specifically targets the Her-2/neu positive cells
and is approved for therapeutic use in patients who are HER-2/neu positive with breast cancer8.
Axillary nodal status in breast cancer is the single most important factor predicting the prognosis
in this disease and thus factors which influence its positivity may provide useful clinically
applicable information. It is possible that if factors are identified to have a significant impact on
axillary nodal spread of disease from the primary breast site then these factors could be used as
tools for regional treatment planning especially in those instances when axillary lymph nodes
sampling is not carried out or when the sentinal node is sampled9. This issue may be of greater
importance when neo-adjunctive chemotherapy is used10 and conversely when the size of breast
cancer is small. The latter occurs when screening mammography is employed11. It is known for
example that the larger a breast cancer the greater is the likelihood that the axillary lymph nodes
will be positive for tumor. Nevertheless axillary nodes can also be involved when the breast
cancer size is small12-17.
In this study the factors predicting axillary lymph node involvement were relatively few. Factors
in univariate analysis that were important predictors of axillary node are listed in Table 1. In our
patients there are some factors that deserve comment. In the group with the higher component of
intraductal disease a lesser percentage of tumors had nodal involvement. This seems to be the
opposite of what would be expected. Similarly one would expect more metastases with an
increased PCNA percentage and this was not noted in our study. Interestingly also the greater the
length of breast-feeding the greater the likelihood of axillary node involvement. This observation
is at odds with the known protective effect of breast-feeding in breast cancer. In multivariate

analysis however only the size of the tumor, skin and nipple involvement and the presence of
disease in the outer quadrant predicted axillary node involvement by breast cancer. Further larger
data are needed from Pakistan in this regard. All of these observations serve to emphasize the
heterogeneous nature of breast cancer and the literature on this aspect of the disease.
Other authors have also attempted to predict axillary lymph node involvement. Factors of
importance have included the patient’s age, tumor size, S phase fraction, ER status, tumor micro
vessel involvement etc. These have some bearing on axillary metastasis but these are not
consistent features in all reports15-18. There is a great explosion of knowledge in the various
molecular markers in breast cancer, for example the importance of the P-53 gene, and HER2/neu
gene. These are important in the clinical behavior of breast cancer and possibly the treatment
implications but their role in disease spread at this time is uncertain1,16.
This study is an attempt to identify predictive factors in breast cancer important for regional
axillary node spread in our clinical setting. Our numbers however are still modest in some areas
such as the molecular markers tested. In poor countries the cost of such tests cannot be borne by
the patients at large. Nonetheless wherever information is available, it would be useful to analyze
it for local relevance. The availability of modem tools of investigations when the disease
presents in an advanced manner and where axillary nodal involvement may be expected can
serve as a useful means in understanding some of the biological and clinical behavior of breast
cancer. It is possible that this information can be translated to treatment strategies in early stage
breast cancer as well.
References
1.Clark GM, Prognostic and predictive factors, in: Diseases of the breast. Harris JR. Lippman
ME, Morrow M, et a!. (eds). Philadelphia, Lippincott-Raven, 2000, pp.489 -514.
2.Patrick LF, Page DL, Weaver D, et al. Prognostic factors in breast cancer (College of
American Pathologists Consensus Statement 1999). Arch. Pathol, Lab. Med; 2000; 124:966 - 75.
3.OsbomeKC, Clark GM, Ravdin PM. Adjuvant systemic therapy of breast cancer, in: diseases
of the breast, in:Harris JR. Lippman ME, Morrow M, et a!. (eds.). Philadelphia,Lippincott Raven, 2000, pp. 599- 632.
4.Shriver MD. Ethnic variation as a key to the biology of human disease (ed.). Ann. Int. Med.,
1997; 5: 401 - 3.
5.EdwardsMJ, Game JW, Vaughan WP, et al. Infiltrating ducts! carcinoma of the breast - the
survival impact of race. 3. Clin. Oncol., 1998; 16: 2693 - 99.
6.DeMichele A, Weber B. Recent advances in breast cancer biology. Current Opin. Oncol.,
1997; 9: 499 - 504.
7.Muss HB, Thor AD, Berry DA, et a!. erb - B 2 expression and response to adjuvant therapy in
women with node positive early breast cancer. N. Eng. 3. Med., 1994; 330: 1260-66.
8.Basegla J. Clinical trials of herceptin (trastuzumab). Eur.J. Cane., 2001; 37 (suppl.). 1S18 -24.
9.Krag D,Weaver D, Ashikaga T,et al. The sentinal node in breast cancer. N. Eng. J. Med.,1998
;14 :941-46.
10.Fisher B, Brown A, Marmounas E, et al. Effect of preoperative chemotherapy on local
regional disease in women with operable breast cancer. Findings from the national surgical
adjuvant breast and bowel project, B18. J. Clin. Oncol., 1997; 15: 2483-93.
11.Barth A, Craig PH, Silverstein Mi, et al. Predictors of axillary lymph node metastasis in
patients with TI breast carcinoma. Cancer, 1997; 79: 1918 -22.

12.Cady B Use of primary Breast cancer characteristics to predict lymph node metastasis.
Cancer, 1997; 79: 1856 -61.
13.Maibenko DC, Linda K, Weiss LK, et al. Axillary lymph node metastasis associated with
small invasive breast carcinomas. Cancer, 1999; 85: 1530 - 35.
14.O’Reilly SM, Campeljohn RS, Barnes DM, et al. Node negative breast cancer, prognostic
subgroups defined by tumor size and flow cytomety. J. CIin. Oncol., 1990; 8: 2040 - 46.
15.Ravdin PM, Dc Laureates M, Vendely T, et al. Prediction of axillary nodal status in breast
cancer patients by the use of prognostic indicators. J. Nat. Can. Inst., 1994; 86:1971-78.
16.Shetty MR, Rieman HM. Tumor size and axillary metastasis, a correlative occurrence in 1244
cases of breast cancer between 1980 and 1995. Eur. 3, Surg. Oncol., 1997 ;23: 139-41.
17.Barth A, Silverstein Mi, Craig PH, et al. Predicting axillary node metastasis: 918 patients with
TI breast carcinoma. Proc. Am. Soc.Clin. Oncol., 1996; 15: A 48.
18.Nathanson SD, zarbo Ri, Wachna DL, et a!. Micro vessels that predict axillary node
metastasis in patients with breast cancer. Arch. Surg., 2000; 135:586-93.

